These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 825020)

  • 21. Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.
    Ries K; Levison ME; Kaye D
    Antimicrob Agents Chemother; 1973 Feb; 3(2):168-74. PubMed ID: 4790584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epileptogenic activity induced by intravenous injection of certain cephalosporins in rats.
    Yu QH; Kitazumi K; Kamei C; Tasaka K
    J Pharmacobiodyn; 1984 Aug; 7(8):586-92. PubMed ID: 6512680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical studies of cefazolin and comparison with other cephalosporins.
    Madhavan T; Quinn EL; Freimer E; Fisher EJ; Cox F; Burch K; Pohlod D
    Antimicrob Agents Chemother; 1973 Nov; 4(5):525-31. PubMed ID: 4791486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefazolin, a new semisynthetic cephalosporin antibiotic. 3. Absorption, excretion and tissue distribution in parenteral administration.
    Nishida M; Matsubara T; Murakawa T; Mine Y; Yokota Y; Goto S; Kuwahara S
    J Antibiot (Tokyo); 1970 Apr; 23(4):184-94. PubMed ID: 5423363
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals.
    Fare LR; Actor P; Sachs C; Phillips L; Joloza M; Pauls JF; Weisbach JA
    Antimicrob Agents Chemother; 1974 Aug; 6(2):150-5. PubMed ID: 15828185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ascitic fluid cephalosporin concentrations: influence of protein binding and serum pharmacokinetics.
    Gerding DN; Peterson LR; Legler DC; Hall WH; Schierl EA
    Antimicrob Agents Chemother; 1978 Aug; 14(2):234-9. PubMed ID: 697350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.
    Actor P; Uri JV; Zajac I; Guarini JR; Phillips L; Pitkin DH; Berges DA; Dunn GL; Hoover JR; Weisbach JA
    Antimicrob Agents Chemother; 1978 May; 13(5):784-90. PubMed ID: 96734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels.
    Nishida M; Murakawa T; Kamimura T; Okada N
    Antimicrob Agents Chemother; 1978 Jul; 14(1):6-12. PubMed ID: 356725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BL-S640, a cephalosporin with a broad spectrum of antibacterial activity: bioavailability and therapeutic properties in rodents.
    Leitner F; Chisholm DR; Tsai YH; Wright GE; Deregis RG; Price KE
    Antimicrob Agents Chemother; 1975 Mar; 7(3):306-10. PubMed ID: 1137382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.
    Srinivasan S; Fu KP; Neu HC
    Antimicrob Agents Chemother; 1981 Feb; 19(2):302-5. PubMed ID: 6214989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.
    Neu HC; Aswapokee P; Fu KP; Ho I; Matthijssen C
    Clin Pharmacol Ther; 1980 May; 27(5):677-85. PubMed ID: 6245831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of ceftezole in patients with normal and impaired renal function.
    Ohkawa M; Kuroda K
    Chemotherapy; 1980; 26(4):242-7. PubMed ID: 7389424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin.
    Actor P; Uri JV; Phillips L; Sachs CS; Guarini JR; Zajac I; Berges DA; Dunn GL; Hoover JR; Weisbach JA
    J Antibiot (Tokyo); 1975 Aug; 28(8):594-601. PubMed ID: 808525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of cefazolin, a new cephalosporin antibiotic.
    Reller LB; Karney WW; Beaty HN; Holmes KK; Turck M
    Antimicrob Agents Chemother; 1973 Apr; 3(4):488-97. PubMed ID: 4790605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.
    Komiya M; Kikuchi Y; Tachibana A; Yano K
    Antimicrob Agents Chemother; 1981 Aug; 20(2):176-83. PubMed ID: 6945066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: cefazolin.
    Lode H; Gebert S; Hendrischk A
    Chemotherapy; 1975; 21(1):19-32. PubMed ID: 1097207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.
    Tsuchiya K; Kida M; Kondo M; Ono H; Takeuchi M; Nishi T
    Antimicrob Agents Chemother; 1978 Oct; 14(4):557-68. PubMed ID: 718154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of absorption and excretion of cefazolin with cephalothin and cephapirin.
    Shimizu T
    Jpn J Antibiot; 1975 Aug; 28(4):542-8. PubMed ID: 1160145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical laboratory studies with a new 7-cyanoalkylthioacylamino cephalosporin: SQ 67,590.
    Miraglia GJ; Basch H; Lukaszow P; Renz KJ; Gadebusch HH
    J Antibiot (Tokyo); 1976 Aug; 29(8):860-2. PubMed ID: 993126
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs.
    Tanayama S; Yoshida K; Adachi K; Kondo T
    Antimicrob Agents Chemother; 1980 Oct; 18(4):511-8. PubMed ID: 6934706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.